Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (4502.T) Financial Performance & Income Statement Overview
Review Takeda Pharmaceutical Company Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Takeda Pharmaceutical Company Limited (4502.T) Income Statement & Financial Overview
Review Takeda Pharmaceutical Company Limited's (4502.T) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Net Income | -$103.16B | $23.84B | $92.05B | $95.25B |
| Depreciation & Amortization | $189.77B | $186.96B | $192.45B | $192.22B |
| Deferred Income Tax | $0.00 | $2.57B | $27.27B | $41.30B |
| Stock Based Compensation | $0.00 | $18.30B | $21.55B | $15.39B |
| Change In Working Capital | $74.93B | $88.76B | -$70.81B | -$189.98B |
| Accounts Receivables | -$13.85B | $12.67B | -$10.04B | -$47.74B |
| Inventory | -$4.99B | $21.24B | -$41.14B | -$10.08B |
| Accounts Payables | $10.33B | $19.63B | $376.00M | -$37.45B |
| Other Working Capital | $83.45B | $54.85B | -$29.65B | -$94.70B |
| Other Non-Cash Items | $30.10B | $63.34B | $18.39B | $541.60B |
| Net Cash From Operating Activities | $191.65B | $352.47B | $280.96B | $159.38B |
| Investments In Property Plant & Equipment | -$92.72B | -$45.09B | -$60.67B | -$137.80B |
| Acquisitions Net | $11.00B | $1.27B | $5.42B | $2.95B |
| Purchases Of Investments | -$3.18B | -$67.57B | -$10.05B | -$12.98B |
| Sales/Maturities Of Investments | $60.45B | $3.56B | $17.80B | $5.32B |
| Other Investing Activities | $399.00M | -$7.72B | -$32.49B | -$18.72B |
| Net Cash Used For Investing Activities | -$24.05B | -$115.56B | -$80.00B | -$161.23B |
| Debt Repayment | -$145.64B | -$470.88B | -$57.09B | $440.53B |
| Common Stock Issued | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock Repurchased | -$49.98B | $0.00 | $0.00 | -$1.88B |
| Dividends Paid | -$9.74B | -$145.45B | -$9.20B | -$138.11B |
| Other Financing Activities | -$61.56B | -$39.64B | -$16.93B | $31.31B |
| Net Cash From Financing Activities | -$266.91B | -$655.97B | -$83.21B | $331.85B |
| Effect Of Forex Changes On Cash | $0.00 | $22.88B | -$41.78B | $17.22B |
| Net Change In Cash | $0.00 | -$364.89B | $54.74B | $599.08B |
| Cash At End Of Period | $385.11B | $494.13B | $859.01B | $804.27B |
| Cash At Beginning Of Period | $494.13B | $859.01B | $804.27B | $205.19B |
| Operating Cash Flow | $191.65B | $352.47B | $259.00B | $159.38B |
| Capital Expenditure | -$48.79B | -$45.09B | -$49.47B | -$137.80B |
| Free Cash Flow | $142.85B | $327.11B | $209.53B | $21.58B |
Takeda Pharmaceutical Company Limited (4502.T) Cash Flow Analysis
Takeda Pharmaceutical Company Limited operates in the Healthcare sector as part of the Drug Manufacturers - Specialty & Generic industry. The company is currently trading at 4217.00 with a market capitalization of N/A.
Cash Flow Overview
Cash flow analysis provides insights into Takeda Pharmaceutical Company Limited's financial health by examining how the company generates and uses cash. This analysis covers three main categories: operating activities, investing activities, and financing activities.
Key Cash Flow Metrics
Financial Position Indicators
Stock Performance Summary
Takeda Pharmaceutical Company Limited has shown the following performance over different time periods:
Company Information
Investment Metrics
Understanding Cash Flow Statements
Cash flow statements are crucial financial documents that track the movement of cash in and out of a business. Unlike income statements that may include non-cash items, cash flow statements focus exclusively on actual cash transactions.
Three Components of Cash Flow:
Operating Activities
Cash generated from core business operations
Investing Activities
Cash used for investments in assets, acquisitions, or securities
Financing Activities
Cash from debt, equity financing, and dividend payments
Data Update: Financial data is updated regularly based on company filings. Last earnings announcement: October 30, 2025.All financial metrics are trailing twelve months (TTM) unless otherwise specified. Currency: JPY. Exchange: JPX.
Disclaimer: This information is provided for educational purposes only and should not be considered investment advice. Please conduct your own research and consult with financial advisors before making investment decisions.
Takeda Pharmaceutical Company Limited (4502.T) Cash Flow Analysis
The cash flow statement reveals the Takeda Pharmaceutical Company Limited (4502.T) liquidity trends, with operating cash flow per share at $608.55, reflecting core business performance. Investing activity changes were -5.70%, indicating capital expenditures or asset sales, while financing activity shifted by -6.78%, showing debt or equity movements. Free cash flow per share was $443.26, highlighting funds available for growth or shareholder returns. Year-over-year change in operating cash flow is 34.36%, demonstrating financial health shifts. For deeper insights, compare these figures with income statements and balance sheets to assess sustainability and strategic priorities.Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan